This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Tenet (THC) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Tenet (THC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Community Health Carries on Hospital Sale for Business Rejig
by Zacks Equity Research
Community Health (CYH) is set to sell hospital units for debt reduction and focusing on profitable business areas.
Community Health Down 16% in a Year: Can it Bounce Back?
by Zacks Equity Research
Community Health (CYH) suffers from high debt and low patient volumes, growth strategies is likely to restore its profitability.
Tenet Healthcare's (THC) Q3 Earnings Beat, Increase Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) third-quarter earnings benefit on the back of USPI and Conifer Segments.
Healthcare Q3 Earnings Due on Nov 5: ACHC, THC, BKD, TVTY
by Zacks Equity Research
Players in the healthcare industry should gain from an increase in revenues, partly offset by a rise in operating costs.
Tenet Healthcare (THC) Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare's (THC) third quarter earnings is likely to gain from solid performance by the Conifer Segment
Tenet Healthcare (THC) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Tenet (THC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth's (UNH) Q3 Earnings Beat, 2018 Guidance Raised
by Zacks Equity Research
UnitedHealth's (UNH) Q3 results gained from higher revenues from both its segments and increase in membership.
Will UnitedHealth's (UNH) Revenue Growth Aid Q3 Earnings?
by Zacks Equity Research
Revenue growth at the company's Optum and United Healthcare segments should drive earnings in Q3.
MEDNAX Buys Radiology Specialists to Expand Business
by Zacks Equity Research
MEDNAX (MD) boosts its radiology business with the acquisition of Radiology Specialists.
Is Tenet Healthcare (THC) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Tenet Healthcare (THC) stock is a good choice for value-oriented investors right now from multiple angles.
Will Hurricane Florence Hurt LifePoint's Patient Volumes?
by Zacks Equity Research
LifePoint's (LPNT) exposure to Carolina might lead to decline in patient visits, possibly hurting business volumes.
Options Traders Expect Huge Moves in Tenet (THC) Stock
by Zacks Equity Research
Tenet (THC) needs investors to pay close attention to the stock based on moves in the options market lately.
Why Is Tenet (THC) Up 1.3% Since Last Earnings Report?
by Zacks Equity Research
Tenet (THC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tenet (THC) Closes the Divestment of Aspen Healthcare in UK
by Zacks Equity Research
Tenet (THC) completes the pending divestiture of Aspen Healthcare to NMC Healthcare in the United Kingdom.
Tenet Healthcare Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Tenet Healthcare Sees Hammer Chart Pattern: Time to Buy?
Here's Why HCA Healthcare (HCA) Must be in Your Portfolio Now
by Zacks Equity Research
Increased earnings guidance, and strong inorganic and organic growth prospects poise HCA Healthcare (HCA) for growth.
Tenet Healthcare (THC) Q2 Earnings Top & Up Y/Y, Revenues Lag
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter earnings impress with solid performances at the Ambulatory Segment.
Tenet Healthcare (THC) Beats Q2 Earnings Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 104.17% and -1.64%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stocks Earnings Due on Aug 6: EVHC, THC, BKD
by Zacks Equity Research
Increased demand for healthcare products and service partly offset by reduced admissions and high costs are likely to affect Q2 earnings of healthcare industry.
Can Tenet Healthcare (THC) Keep Earnings Beat Alive in Q2?
by Zacks Equity Research
Tenet Healthcare (THC) is likely to repeat its success story in Q2 on the back of a strong performance at the Conifer segment as well as its key initiatives.
Envision Healthcare (EVHC) Q2 Earnings: What's in Store?
by Zacks Equity Research
Envision Healthcare (EVHC) Q2 earnings should gain from higher revenues from thePhysician Service segment and gains from cost control initiatives.
Should You Buy Tenet Healthcare (THC) Ahead of Earnings?
by Zacks Equity Research
Tenet Healthcare (THC) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Will Revenue Growth Drive Teladoc (TDOC) Q2 Earnings Higher?
by Zacks Equity Research
Teladoc (TDOC) Q2 earnings to gain from increased patient visits and subscription fees.
Will Higher Revenues Aid UnitedHealth's (UNH) Q2 Earnings?
by Zacks Equity Research
Continued strong performance across the company to aid UnitedHealth's (UNH) results.